These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

573 related items for PubMed ID: 26172401

  • 1. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
    Park IK, Mundy-Bosse B, Whitman SP, Zhang X, Warner SL, Bearss DJ, Blum W, Marcucci G, Caligiuri MA.
    Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
    Park IK, Mishra A, Chandler J, Whitman SP, Marcucci G, Caligiuri MA.
    Blood; 2013 Mar 14; 121(11):2064-73. PubMed ID: 23321254
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F, Steudel C, Oelschlägel U, Mohr B, Koch S, Ehninger G, Thiede C.
    Ann Hematol; 2010 Jul 14; 89(7):653-62. PubMed ID: 20119833
    [Abstract] [Full Text] [Related]

  • 4. Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD+ acute myeloid leukemia cells.
    Liu Y, Wei J, Liu J, Ma W, Duan Y, Liu D.
    Oncol Lett; 2021 May 14; 21(5):397. PubMed ID: 33777220
    [Abstract] [Full Text] [Related]

  • 5. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL.
    Dumas PY, Naudin C, Martin-Lannerée S, Izac B, Casetti L, Mansier O, Rousseau B, Artus A, Dufossée M, Giese A, Dubus P, Pigneux A, Praloran V, Bidet A, Villacreces A, Guitart A, Milpied N, Kosmider O, Vigon I, Desplat V, Dusanter-Fourt I, Pasquet JM.
    Haematologica; 2019 Oct 14; 104(10):2017-2027. PubMed ID: 30923103
    [Abstract] [Full Text] [Related]

  • 6. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia.
    Dumas PY, Villacreces A, Guitart AV, El-Habhab A, Massara L, Mansier O, Bidet A, Martineau D, Fernandez S, Leguay T, Pigneux A, Vigon I, Pasquet JM, Desplat V.
    Clin Cancer Res; 2021 Nov 01; 27(21):6012-6025. PubMed ID: 34400415
    [Abstract] [Full Text] [Related]

  • 7. CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
    Waldeck S, Rassner M, Keye P, Follo M, Herchenbach D, Endres C, Charlet A, Andrieux G, Salzer U, Boerries M, Duyster J, von Bubnoff N.
    Mol Oncol; 2020 Apr 01; 14(4):779-794. PubMed ID: 31955503
    [Abstract] [Full Text] [Related]

  • 8. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
    Mori M, Kaneko N, Ueno Y, Yamada M, Tanaka R, Saito R, Shimada I, Mori K, Kuromitsu S.
    Invest New Drugs; 2017 Oct 01; 35(5):556-565. PubMed ID: 28516360
    [Abstract] [Full Text] [Related]

  • 9. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
    Seedhouse CH, Hunter HM, Lloyd-Lewis B, Massip AM, Pallis M, Carter GI, Grundy M, Shang S, Russell NH.
    Leukemia; 2006 Dec 01; 20(12):2130-6. PubMed ID: 17066094
    [Abstract] [Full Text] [Related]

  • 10. MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
    Zhang X, Li B, Yu J, Dahlström J, Tran AN, Björkholm M, Xu D.
    Ann Hematol; 2018 Jan 01; 97(1):63-72. PubMed ID: 29080039
    [Abstract] [Full Text] [Related]

  • 11. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M.
    Clin Cancer Res; 2014 May 01; 20(9):2363-74. PubMed ID: 24619500
    [Abstract] [Full Text] [Related]

  • 12. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P, Xiao X, Zhang Y, Zhang B, Li D, Liu M, Xie X, Liu C, Liu P, Ren R.
    J Hematol Oncol; 2021 Jul 03; 14(1):105. PubMed ID: 34217323
    [Abstract] [Full Text] [Related]

  • 13. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J, Jia MY, Fang WY, Chen XJ, Mu LL, Wang ZY, Shen Y, Xiang RF, Wang LN, Wang L, Jiang CH, Jiang JL, Zhang WJ, Sun YD, Chang L, Gao WH, Wang Y, Li JM, Hong DL, Liang AB, Hu J.
    Blood; 2020 Apr 23; 135(17):1472-1483. PubMed ID: 32315388
    [Abstract] [Full Text] [Related]

  • 14. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
    Yu Z, Du J, Hui H, Kan S, Huo T, Zhao K, Wu T, Guo Q, Lu N.
    Theranostics; 2021 Apr 23; 11(1):93-106. PubMed ID: 33391463
    [Abstract] [Full Text] [Related]

  • 15. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
    Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary CR, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C, Fischer T.
    Blood; 2005 Jan 01; 105(1):335-40. PubMed ID: 15345593
    [Abstract] [Full Text] [Related]

  • 16. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, Baker SD.
    Blood; 2013 Nov 21; 122(22):3607-15. PubMed ID: 24046014
    [Abstract] [Full Text] [Related]

  • 17. Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation.
    Ahmad R, Liu S, Weisberg E, Nelson E, Galinsky I, Meyer C, Kufe D, Kharbanda S, Stone R.
    Mol Cancer Res; 2010 Jul 21; 8(7):986-93. PubMed ID: 20571062
    [Abstract] [Full Text] [Related]

  • 18. Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.
    Patel RK, Weir MC, Shen K, Snyder D, Cooper VS, Smithgall TE.
    PLoS One; 2019 Jul 21; 14(12):e0225887. PubMed ID: 31790499
    [Abstract] [Full Text] [Related]

  • 19. G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.
    Lee HK, Kim HW, Lee IY, Lee J, Lee J, Jung DS, Lee SY, Park SH, Hwang H, Choi JS, Kim JH, Kim SW, Kim JK, Cools J, Koh JS, Song HJ.
    Blood; 2014 Apr 03; 123(14):2209-19. PubMed ID: 24532805
    [Abstract] [Full Text] [Related]

  • 20. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
    Fathi AT, Blonquist TM, Hernandez D, Amrein PC, Ballen KK, McMasters M, Avigan DE, Joyce R, Logan EK, Hobbs G, Brunner AM, Joseph C, Perry AM, Burke M, Behnan T, Foster J, Bergeron MK, Moran JA, Ramos AY, Som TT, Rae J, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Levis MJ.
    Cancer; 2018 Jan 15; 124(2):306-314. PubMed ID: 28960265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.